Revelation Biosciences Inc Cash Flow Conversion Efficiency
Revelation Biosciences Inc cash flow conversion efficiency. Based on the latest financial reports, Revelation Biosciences Inc (REVB) has a cash flow conversion efficiency ratio of -0.254x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.56 Million) by net assets ($10.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Revelation Biosciences Inc (2016–2025)
Cash flow conversion efficiency of Revelation Biosciences Inc from 2016 to 2025. This chart illustrates how Revelation Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Revelation Biosciences Inc share price for real-time trading data and today's change.
Revelation Biosciences Inc Cash Flow Conversion Ratio Explained
Revelation Biosciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Revelation Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Revelation Biosciences Inc ranked by their cash flow conversion efficiency. Also see Revelation Biosciences Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Archidply Decor Limited
NSE:ADL
|
0.012x |
|
Dhruv Consultancy Services Limited
NSE:DHRUV
|
0.035x |
|
Largo SAS
PA:ALLGO
|
3.901x |
|
Enthusiast Gaming Holdings Inc
TO:EGLX
|
1.951x |
|
PREMIER1 Lithium Ltd
AU:PLC
|
-0.106x |
|
Sonim Technologies Inc
NASDAQ:SONM
|
1.624x |
|
International Biotechnology Trust plc
LSE:IBT
|
0.126x |
|
OMG Group Ltd
AU:OMG
|
-0.052x |
Annual Cash Flow Conversion Efficiency for Revelation Biosciences Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Revelation Biosciences Inc from 2016 to 2025. Review Revelation Biosciences Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $8.86 Million | $-8.27 Million | -0.933x | +76.02% |
| 2024-12-31 | $4.71 Million | $-18.32 Million | -3.891x | -255.02% |
| 2023-12-31 | $6.65 Million | $-7.29 Million | -1.096x | +89.72% |
| 2022-12-31 | $1.05 Million | $-11.22 Million | -10.660x | -109.56% |
| 2021-12-31 | $-99.47K | $-11.09 Million | 111.497x | +3515821.17% |
| 2020-12-31 | $67.82 Million | $-215.07K | -0.003x | +100.00% |
| 2019-12-31 | $-3.64K | $41.09 Million | -11293.568x | -9182593.30% |
| 2018-12-31 | $264.89 Million | $32.58 Million | 0.123x | -4.50% |
| 2017-12-31 | $188.28 Million | $24.25 Million | 0.129x | +87.38% |
| 2016-12-31 | $168.76 Million | $11.60 Million | 0.069x | -- |
About Revelation Biosciences Inc
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregul… Read more